MiR-133a acts as an anti-oncogene in Hepatocellular carcinoma by inhibiting FOSL2 through TGF-β/Smad3 signaling pathway - 20/09/18
páginas | 9 |
Iconografías | 9 |
Vídeos | 0 |
Otros | 0 |
Graphical abstract |
Highlights |
• | MiR-133a is downregulated in HCC tissues and HCC cell lines. |
• | Overexpression of miR-133a suppresses HCC cell growth, proliferation, migration, invasion and promotes cell apoptosis. |
• | FOSL2 is a target of miR-133a and overexpression of FOSL2 reverses the role of miR-133a in HCC cells. |
• | MiR-133a suppresses HCC cell biological behaviors through TGF-β/Smad3 signaling pathway. |
• | MiR-133a inhibits the growth of tumor cell xenografts in nude mice. |
Abstract |
Hepatocellular carcinoma (HCC), one of the most common maligant cancers in the world, is difficult to diagnose in the early time. MicroRNAs (miRNAs), small non-coding RNAs, perform vital functions in cellular differentiation, metabolism and physiological processes. MiR-133a acts as a tumor suppressor in breast, lung and gastric cancer, while the molecular circadian mechanism has not been clear in HCC. In the present study, we certified that the expression of miR-133a decreased in HCC tissues and cell lines and that miR-133a inhibited proliferation, migration and invasion of hepatocellular carcinoma cells. Fos-related antigen 2 (FOSL2), also named FRA-2, was predicted to be a downstream target of miR-133a based on bioinformatic analysis and the prediction was verified by Western Blot, qRT-PCR and luciferase reporter assay. In addition, there was a negative correlation between miR-133a and FOSL2 expression in HCC samples. Furthermore, we verified that overexpression of miR-133a suppressed biological behaviour of HCC through TGF-β/Smad3 signaling pathway. In brief, miR-133a may be a potential prognostic biomarker and may thus be a new therapy in HCC.
El texto completo de este artículo está disponible en PDF.Keywords : miR-133a, FOSL2, Hepatocellular, Carcinoma, TGF-β
Esquema
Vol 107
P. 168-176 - novembre 2018 Regresar al númeroBienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
La compra de artículos no está disponible en este momento.
¿Ya suscrito a @@106933@@ revista ?